These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 26750639

  • 21. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X, El Khoury AC, Brouillette M, Smith D, Joshi K.
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [Abstract] [Full Text] [Related]

  • 22. Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics.
    Lafeuille MH, Tandon N, Tiggelaar S, Kamstra R, Lefebvre P, Kim E, Yue Y, Joshi K.
    Drugs Real World Outcomes; 2018 Mar; 5(1):81-90. PubMed ID: 29363022
    [Abstract] [Full Text] [Related]

  • 23. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A, Xie L, Kariburyo F, Zhang Q, Gore M.
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [Abstract] [Full Text] [Related]

  • 24. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
    Cai C, Kozma C, Patel C, Benson C, Yunusa I, Zhao P, Reeder G, Narasimhan M, Bank RL.
    J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
    [Abstract] [Full Text] [Related]

  • 25. Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay.
    Patel C, Pilon D, Morrison L, Holiday C, Lafeuille MH, Lefebvre P, Benson C.
    Curr Med Res Opin; 2023 Aug; 39(8):1157-1166. PubMed ID: 37461233
    [Abstract] [Full Text] [Related]

  • 26. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
    Muser E, Kozma CM, Benson CJ, Mao L, Starr HL, Alphs L, Fastenau J.
    J Med Econ; 2015 Aug; 18(8):637-45. PubMed ID: 25851616
    [Abstract] [Full Text] [Related]

  • 27. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
    Rosenheck RA, Leslie DL, Sint KJ, Lin H, Li Y, McEvoy JP, Byerly MJ, Hamer RM, Swartz MS, Stroup TS.
    Psychiatr Serv; 2016 Oct 01; 67(10):1124-1130. PubMed ID: 27247177
    [Abstract] [Full Text] [Related]

  • 28. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate.
    Patel C, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Tandon N, El Khoury AC.
    Drugs Real World Outcomes; 2020 Mar 01; 7(1):19-29. PubMed ID: 31786737
    [Abstract] [Full Text] [Related]

  • 29. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis.
    Pilon D, Amos TB, Kamstra R, Manceur AM, El Khoury AC, Lefebvre P.
    Curr Med Res Opin; 2019 Jan 01; 35(1):41-49. PubMed ID: 30106313
    [Abstract] [Full Text] [Related]

  • 30. De novo cost-utility analysis of oral paliperidone in the treatment of schizoaffective disorder.
    Přibylová L, Kolek M, Veselá Š, Duba J, Šlesinger J, Dolečková J.
    J Psychiatr Res; 2015 Nov 01; 70():33-7. PubMed ID: 26424421
    [Abstract] [Full Text] [Related]

  • 31. Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection.
    Mesones-Peral JE, Gurillo-Muñoz P, Sánchez-Sicilia MP, Miller A, Griñant-Fernández A.
    Rev Psiquiatr Salud Ment; 2017 Nov 01; 10(1):33-37. PubMed ID: 27053545
    [Abstract] [Full Text] [Related]

  • 32. Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder.
    Benson C, Patel C, Lee I, Shaikh NF, Wang Y, Zhao X, Near AM.
    J Manag Care Spec Pharm; 2024 Sep 01; 30(9):954-966. PubMed ID: 38831661
    [Abstract] [Full Text] [Related]

  • 33. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.
    Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K.
    Curr Med Res Opin; 2019 Mar 01; 35(3):407-416. PubMed ID: 30556739
    [Abstract] [Full Text] [Related]

  • 34. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, Mavros P, Lefebvre P.
    CNS Drugs; 2021 May 01; 35(5):469-481. PubMed ID: 33909272
    [Abstract] [Full Text] [Related]

  • 35. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
    Basu A, Benson C, Alphs L.
    J Manag Care Spec Pharm; 2018 Aug 01; 24(8):759-768. PubMed ID: 30058979
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K, Lin J, Lingohr-Smith M, Fu DJ.
    J Med Econ; 2015 Aug 01; 18(8):629-36. PubMed ID: 25800457
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
    Lafeuille MH, Grittner AM, Fortier J, Muser E, Fasteneau J, Duh MS, Lefebvre P.
    Am J Health Syst Pharm; 2015 Mar 01; 72(5):378-89. PubMed ID: 25694413
    [Abstract] [Full Text] [Related]

  • 40. Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong.
    Choon JWY, Wu DBC, Chong HY, Lo WTL, Chong CSY, Chung WS, Chui EMC, Tomlinson B, Lee VWY, Lee SC, Lee KKC.
    J Med Econ; 2019 Mar 01; 22(3):273-279. PubMed ID: 30561238
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.